EE20/DRSP (YAZ, BAY86-5300) + Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Oral Contraceptive
Conditions
Oral Contraceptive
Trial Timeline
Apr 1, 2010 → Oct 1, 2011
NCT ID
NCT01076582About EE20/DRSP (YAZ, BAY86-5300) + Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)
EE20/DRSP (YAZ, BAY86-5300) + Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon) is a phase 3 stage product being developed by Bayer for Oral Contraceptive. The current trial status is completed. This product is registered under clinical trial identifier NCT01076582. Target conditions include Oral Contraceptive.
What happened to similar drugs?
5 of 20 similar drugs in Oral Contraceptive were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01076582 | Phase 3 | Completed |
Competing Products
20 competing products in Oral Contraceptive